Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.
Srdan Verstovsek
Research Funding - Incyte
Ruben A. Mesa
Research Funding - Incyte
Jason R. Gotlib
Consultant or Advisory Role - Incyte
Research Funding - Incyte
Vikas Gupta
Consultant or Advisory Role - Incyte; Novartis; Sanofi ; YM BioSciences
Honoraria - Incyte; Novartis
Other Remuneration - Incyte; Novartis
John F. DiPersio
No relevant relationships to disclose
John V. Catalano
Consultant or Advisory Role - Incyte; Novartis
Honoraria - Incyte; Novartis
Michael W.N. Deininger
Honoraria - Incyte
Carole Brennan Miller
Consultant or Advisory Role - Incyte; Novartis
Honoraria - Incyte; Novartis
Richard T. Silver
Consultant or Advisory Role - Incyte
Stock Ownership - Incyte
Honoraria - Incyte
Research Funding - Incyte
Moshe Talpaz
No relevant relationships to disclose
Elliott F. Winton
Consultant or Advisory Role - Incyte (U)
Honoraria - Incyte
Jimmie Huling Harvey
No relevant relationships to disclose
Murat O. Arcasoy
Research Funding - Incyte
Elizabeth O. Hexner
Research Funding - Incyte
Roger M. Lyons
Research Funding - Amgen; Celgene; Incyte; Novartis; Telik
Ronald Paquette
No relevant relationships to disclose
Azra Raza
No relevant relationships to disclose
William Sun
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Hagop Kantarjian
Research Funding - Incyte